TY - JOUR
T1 - Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab
T2 - A Case Report
AU - Rojas-Carabali, William
AU - Boada-Robayo, Laura
AU - Chacón-Zambrano, Daniela
AU - Criollo Porras, Eveling
AU - Kerguelén Dumar, Valentina
AU - de-la-Torre, Alejandra
N1 - Publisher Copyright:
© 2022 Taylor & Francis Group, LLC.
PY - 2022/9/23
Y1 - 2022/9/23
N2 - Purpose: To report a case of multiple sclerosis (MS) development in a patient with Juvenile Idiopathic Arthritis (JIA) and bilateral intermediate uveitis (IU) treated with Adalimumab. Case report: A 21-year-old Colombian woman diagnosed with JIA and bilateral refractory IU treated with methotrexate and Adalimumab with difficult control of the disease and multiple ocular complications. Eight years after starting Adalimumab, the patient presented paresthesia in the left upper limb. Radiologic findings in the brain and cervical spine MRI confirmed the diagnosis of MS. Conclusions: We reported the first case of MS development in a patient with JIA treated with Adalimumab and the third in a patient with noninfectious uveitis treated with anti-TNFα. It remains uncertain whether MS is secondary to anti-TNFα therapy or is linked to a polyautoimmunity phenomenon.
AB - Purpose: To report a case of multiple sclerosis (MS) development in a patient with Juvenile Idiopathic Arthritis (JIA) and bilateral intermediate uveitis (IU) treated with Adalimumab. Case report: A 21-year-old Colombian woman diagnosed with JIA and bilateral refractory IU treated with methotrexate and Adalimumab with difficult control of the disease and multiple ocular complications. Eight years after starting Adalimumab, the patient presented paresthesia in the left upper limb. Radiologic findings in the brain and cervical spine MRI confirmed the diagnosis of MS. Conclusions: We reported the first case of MS development in a patient with JIA treated with Adalimumab and the third in a patient with noninfectious uveitis treated with anti-TNFα. It remains uncertain whether MS is secondary to anti-TNFα therapy or is linked to a polyautoimmunity phenomenon.
UR - http://www.scopus.com/inward/record.url?scp=85139155136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139155136&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/e7f664a9-948d-38d7-bcad-924e61b34cc0/
U2 - 10.1080/09273948.2022.2113800
DO - 10.1080/09273948.2022.2113800
M3 - Article
C2 - 36150118
AN - SCOPUS:85139155136
SN - 0927-3948
SP - 1
EP - 4
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
ER -
